Co-Authors
This is a "connection" page, showing publications co-authored by STEVEN G WAGUESPACK and MOUHAMMED A HABRA.
Connection Strength
2.551
-
Image in endocrinology: adrenal pseudocyst. J Clin Endocrinol Metab. 2005 May; 90(5):3067-8.
Score: 0.256
-
Venous thromboembolism in adrenocortical carcinoma: a retrospective analysis. Oncologist. 2024 Jul 05; 29(7):575-580.
Score: 0.242
-
Incidence and Geographical Distribution of Adrenocortical Carcinoma: Retrospective Analysis of a State Cancer Registry. Endocr Pract. 2024 Jan; 30(1):25-30.
Score: 0.230
-
TNM Staging and Overall Survival in Patients With Pheochromocytoma and Sympathetic Paraganglioma. J Clin Endocrinol Metab. 2023 04 13; 108(5):1132-1142.
Score: 0.222
-
Temporal Trends in Outcomes in Patients With Adrenocortical Carcinoma: A Multidisciplinary Referral-center Experience. J Clin Endocrinol Metab. 2022 04 19; 107(5):1239-1246.
Score: 0.208
-
Preexisting adrenal masses in patients with adrenocortical carcinoma: clinical and radiological factors contributing to delayed diagnosis. Endocrine. 2016 Feb; 51(2):351-9.
Score: 0.130
-
Adrenocortical carcinoma: clinical outcomes and prognosis of 330 patients at a tertiary care center. Eur J Endocrinol. 2013 Dec; 169(6):891-899.
Score: 0.115
-
Adrenal ganglioneuroma: features and outcomes of 27 cases at a referral cancer centre. Clin Endocrinol (Oxf). 2014 Mar; 80(3):342-7.
Score: 0.115
-
A retrospective cohort analysis of the efficacy of adjuvant radiotherapy after primary surgical resection in patients with adrenocortical carcinoma. J Clin Endocrinol Metab. 2013 Jan; 98(1):192-7.
Score: 0.108
-
Cushing syndrome secondary to ectopic adrenocorticotropic hormone secretion: the University of Texas MD Anderson Cancer Center Experience. Cancer. 2011 Oct 01; 117(19):4381-9.
Score: 0.096
-
Multiple endocrine neoplasia type 2B with a RET proto-oncogene A883F mutation displays a more indolent form of medullary thyroid carcinoma compared with a RET M918T mutation. Thyroid. 2011 Feb; 21(2):189-92.
Score: 0.095
-
SDHB-Associated Pheochromocytomas: What is Their Clinical Behavior? Ann Surg Oncol. 2024 Dec; 31(13):9007-9013.
Score: 0.062
-
High-Specific-Activity 131 I-MIBG for the Treatment of Advanced Pheochromocytoma and Paraganglioma. Clin Nucl Med. 2024 Jul 01; 49(7):610-620.
Score: 0.060
-
Management of adrenocorticotropic hormone-secreting neuroendocrine tumors and the role of bilateral adrenalectomy in ectopic Cushing syndrome. Surgery. 2022 08; 172(2):559-566.
Score: 0.052
-
Immune checkpoint inhibitor related hypophysitis: diagnostic criteria and recovery patterns. Endocr Relat Cancer. 2021 06 02; 28(7):419-431.
Score: 0.049
-
Endocrine surgery in the Coronavirus disease 2019 pandemic: Surgical Triage Guidelines. Head Neck. 2020 06; 42(6):1325-1328.
Score: 0.045
-
The Clinical Impact of [68 Ga]-DOTATATE PET/CT for the Diagnosis and Management of Ectopic Adrenocorticotropic Hormone - Secreting Tumours. Clin Endocrinol (Oxf). 2019 08; 91(2):288-294.
Score: 0.043
-
Prognostic Significance of Circulating RET M918T Mutated Tumor DNA in Patients With Advanced Medullary Thyroid Carcinoma. J Clin Endocrinol Metab. 2017 09 01; 102(9):3591-3599.
Score: 0.038
-
Cushing Syndrome: Diagnostic Workup and Imaging Features, With Clinical and Pathologic Correlation. AJR Am J Roentgenol. 2017 Jul; 209(1):19-32.
Score: 0.037
-
Bone Metastases and Skeletal-Related Events in Medullary Thyroid Carcinoma. J Clin Endocrinol Metab. 2016 12; 101(12):4871-4877.
Score: 0.035
-
Efficacy of the Natural Clay, Calcium Aluminosilicate Anti-Diarrheal, in Reducing Medullary Thyroid Cancer-Related Diarrhea and Its Effects on Quality of Life: A Pilot Study. Thyroid. 2015 Oct; 25(10):1085-90.
Score: 0.033
-
Efficacy and tolerability of different starting doses of sorafenib in patients with differentiated thyroid cancer. Oncologist. 2014 May; 19(5):477-82.
Score: 0.030
-
Role of salvage targeted therapy in differentiated thyroid cancer patients who failed first-line sorafenib. J Clin Endocrinol Metab. 2014 Jun; 99(6):2086-94.
Score: 0.030
-
The characterization of pheochromocytoma and its impact on overall survival in multiple endocrine neoplasia type 2. J Clin Endocrinol Metab. 2013 Nov; 98(11):E1813-9.
Score: 0.029
-
Bone metastases and skeletal-related events in patients with malignant pheochromocytoma and sympathetic paraganglioma. J Clin Endocrinol Metab. 2013 Apr; 98(4):1492-7.
Score: 0.028
-
The noninvestigational use of tyrosine kinase inhibitors in thyroid cancer: establishing a standard for patient safety and monitoring. J Clin Endocrinol Metab. 2013 Jan; 98(1):31-42.
Score: 0.027
-
Treatment with sunitinib for patients with progressive metastatic pheochromocytomas and sympathetic paragangliomas. J Clin Endocrinol Metab. 2012 Nov; 97(11):4040-50.
Score: 0.027
-
Clinical benefits of systemic chemotherapy for patients with metastatic pheochromocytomas or sympathetic extra-adrenal paragangliomas: insights from the largest single-institutional experience. Cancer. 2012 Jun 01; 118(11):2804-12.
Score: 0.025
-
Acute-onset ectopic adrenocorticotropic hormone syndrome secondary to metastatic endometrioid carcinoma of the ovaries as a fatal complication. J Clin Oncol. 2011 Jun 01; 29(16):e462-4.
Score: 0.024
-
Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators. J Clin Endocrinol Metab. 2011 Mar; 96(3):717-25.
Score: 0.024
-
A catecholamine crisis on Mount Kilimanjaro: a hypoxia effect? J Travel Med. 2010 Nov-Dec; 17(6):424-6.
Score: 0.023
-
Parathyroid carcinoma: a 22-year experience. Head Neck. 2004 Aug; 26(8):716-26.
Score: 0.015